PMGC Holdings (ELAB) Cash from Investing Activities (2022 - 2026)
PMGC Holdings (ELAB) posted Cash from Investing Activities of -$2.5 million for Q1 2026, down 352.68% sequentially from -$548642.0 in Q4 2025, and down 1053.46% YoY from $260485.0 in Q1 2025.
PMGC Holdings (ELAB) Cash from Investing Activities (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Cash from Investing Activities for 5 years, with the latest figure at -$2.5 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 1053.46% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.0 million (down 556.49% YoY) and the FY2025 annual result came in at -$2.8 million, down 352.89% from the prior year.
- Cash from Investing Activities slipped to -$2.5 million in Q1 2026 per ELAB's latest filing, from -$548642.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $33.4 million in Q4 2022 and troughed at -$2.5 million in Q1 2026.
- A 5-year average of $2.5 million and a median of -$62320.0 in 2024 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 415.85% in 2025, down 4296.07% in 2025.
- Over 5 years, Cash from Investing Activities stood at $33.4 million in 2022, then plunged by 100.03% to -$11191.0 in 2023, then slumped by 3823.55% to -$439084.0 in 2024, then declined by 24.95% to -$548642.0 in 2025, then slumped by 352.68% to -$2.5 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2.5 million, -$548642.0, and -$2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -3.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.48 Mn |
| Mar 31, 2026 | -2.48 Mn |
| Dec 31, 2025 | -548,642.00 |
| Dec 31, 2025 | -548,642.00 |
| Sep 30, 2025 | -2.20 Mn |
| Sep 30, 2025 | -2.20 Mn |
| Jun 30, 2025 | 196,840.00 |
| Jun 30, 2025 | 196,840.00 |
| Mar 31, 2025 | -215,319.00 |
| Mar 31, 2025 | -215,319.00 |
| Dec 31, 2024 | -439,084.00 |
| Dec 31, 2024 | -439,084.00 |
| Sep 30, 2024 | -50,000.00 |
| Sep 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -62,320.00 |
| Jun 30, 2024 | -62,320.00 |
| Mar 31, 2024 | -59,160.00 |
| Mar 31, 2024 | -59,160.00 |
| Mar 31, 2023 | -11,191.00 |
| Mar 31, 2023 | -11,191.00 |